Table 2. Landmark trials in second-line treatment of GEJ and gastric cancers.

Authors, years (study name)	Treatment regimen	Total patients	ORR/CR	mPFS (months); HR, P value	mOS (months); HR, P value
Fuchs et al., 2014 (REGARD)	Ramucirumab & best supportive care vs. placebo & best supportive care	355	3%/<1%; 3%/0%	2.1 vs. 1.3; HR 0.483, P<0.0001	5.2 vs. 3.8; HR 0.776, P=0.47
Wilke et al., 2019 (RAINBOW)	Ramucirumab & paclitaxel vs. placebo & paclitaxel	665	28%/<1%; 16%/<1%	4.4 vs. 2.9; HR 0.635, P<0.0001	9.6 vs. 7.4; HR 0.807, P=0.017
Fuchs et al., 2018 (KEYNOTE-059)	Pembrolizumab	259	11.6%/2.3%	2.0	5.6
Kang et al., 2017 (ATTRACTION-2)	Nivolumab vs. placebo	493	11.2%/0%; 0%/0%	1.61 vs. 1.45; HR 0.60, P<0.0001	5.26 vs. 4.14; HR 0.63, P<0.0001
Doi et al., 2019 (JAVELIN)	Avelumab	40	10%/2.5%	2.4	9.1

NR, not reported.